Chemotherapy-elicited upregulation of NKG2D and DNAM-1 ligands as a therapeutic target in multiple myeloma.

Autor:	Soriani A; Department of Molecular Medicine; Instituto Pasteur-Fondazione Cenci Bolognetti; Sapienza University of Rome; Rome, Italy., Fionda C; Department of Molecular Medicine; Instituto Pasteur-Fondazione Cenci Bolognetti; Sapienza University of Rome; Rome, Italy., Ricci B; Department of Molecular Medicine; Instituto Pasteur-Fondazione Cenci Bolognetti; Sapienza University of Rome; Rome, Italy., Iannitto ML; Department of Molecular Medicine; Instituto Pasteur-Fondazione Cenci Bolognetti; Sapienza University of Rome; Rome, Italy., Cippitelli M; Department of Molecular Medicine; Instituto Pasteur-Fondazione Cenci Bolognetti; Sapienza University of Rome; Rome, Italy., Santoni A; Department of Molecular Medicine; Instituto Pasteur-Fondazione Cenci Bolognetti; Sapienza University of Rome; Rome, Italy.
Jazyk:	angličtina
Zdroj:	Oncoimmunology [Oncoimmunology] 2013 Dec 01; Vol. 2 (12), pp. e26663. Date of Electronic Publication: 2013 Oct 22.
DOI:	10.4161/onci.26663
Abstrakt:	Malignant cells constitutively express Natural killer group 2, member D (NKG2D) or DNAX Accessory Molecule-1 (DNAM-1) ligands, yet they are often unable to trigger a robust cytotoxic cell response. It may be therapeutically useful to implement strategies aimed at increasing the density of NKG2D and DNAM-1 ligands on the surface of cancer cells, endowing them with the capacity to activate potent antitumor natural killer-cell responses.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu